Biosimilar DMARDs: What Does the Future Hold? - Wikidata - awgldk - TriplyDB

Biosimilar DMARDs: What Does the Future Hold?

Biosimilar DMARDs: What Does the Future Hold?

http://www.wikidata.org/entity/Q38760042

about

Pharmacoeconomics of Biosimilars: What Is There to Gain from Them?

P2860

Q38893192-03B98EED-860C-4F7F-9211-6DC5ECE8DF33

P2860

Biosimilar DMARDs: What Does the Future Hold?

http://www.wikidata.org/entity/Q38760042

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Biosimilar DMARDs: What Does the Future Hold?

@en

type

label

Biosimilar DMARDs: What Does the Future Hold?

@en

prefLabel

Biosimilar DMARDs: What Does the Future Hold?

@en

P1433

Q38760042-F87F6AD8-C62B-424F-BB29-65E1178F5E81

P1476

Q38760042-9CA000F1-A113-4715-B7DD-AB585E5E89FE

P2093

Q38760042-72EDBE09-BF95-4A92-BED0-B1E536317BC1

P2860

Q38760042-018231FE-BBE5-4BDF-8DAE-BACF49EC2107

Q38760042-0595D797-CB71-4F96-B9B1-3465125844A1

Q38760042-128A8CB8-95B4-4D79-A9F9-1966FF9431F4

Q38760042-1E12EB97-CDB7-4313-8A29-9F3D6BEA0487

Q38760042-259ECBFE-5195-4F41-B319-F50CB3444455

Q38760042-3088643D-21DA-411F-A372-E718B68ED0EC

Q38760042-3CF78F69-BF4C-4D97-8272-00DB35BAB2E6

Q38760042-610F8E32-BBB8-452E-A8A5-E907C53C4CE4

Q38760042-76F76788-60F4-4AA8-99FB-FB8F1F388B92

Q38760042-787611AD-E754-4E92-9E8A-CD61BEB06BA5

P2888

Q38760042-81A91CF6-DCD8-4206-A9B1-EE5262A1268E

P304

Q38760042-AEA07025-B32F-4B4D-AC1D-25C7EA014DA7

P31

Q38760042-F3CFD29B-CCB2-4704-BB7F-16DA49B2FB12

P356

Q38760042-93164BE0-BBEC-4D96-9771-50E9F09E4216

P433

Q38760042-8C0CA2A6-BFD2-4C13-B780-4AC32D2AAF92

P478

Q38760042-C6B6CBBC-273E-4210-94EE-C20145A4C9CF

P50

Q38760042-633030A1-B720-4336-B802-53889C3B5EC0

Q38760042-D3F68ECC-B6AC-4C5E-8D96-D9519AD91AC7

P577

Q38760042-B40787CB-DC7C-423B-B97F-5E5548655631

P6179

Q38760042-67714543-38ED-4565-A2A4-883EB9A1D349

P698

Q38760042-06609933-3946-4B5A-8911-F053EDEF0334

P356

S40265-016-0556-5

P1433

P1476

Biosimilar DMARDs: What Does the Future Hold?

@en

P2093

Filipe Araújo

http://www.w3.org/2001/XMLSchema#string

P2860

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update

Is extrapolation of the safety and efficacy data in one indication to another appropriate for biosimilars?

Budget impact analysis of biosimilar infliximab (CT-P13) for the treatment of rheumatoid arthritis in six Central and Eastern European countries.

Biosimilars: the science of extrapolation.

The Budget Impact of Biosimilar Infliximab (Remsima®) for the Treatment of Autoimmune Diseases in Five European Countries

Physicochemical characterization of Remsima.

Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS study

Clinical pharmacokinetics and use of infliximab.

A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study.

A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study

P2888

s40265-016-0556-5

P304

629-637

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40265-016-0556-5

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

76

http://www.w3.org/2001/XMLSchema#string

P50

João E. Fonseca

P577

2016-03-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1022398216

http://www.w3.org/2001/XMLSchema#string

P698

26941025

http://www.w3.org/2001/XMLSchema#string